๐๏ธ Verified NIH Record โข Updated 2026-02-12
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348)
๐ต Active, Not Recruiting Phase2 ๐ Investigational Drug / Biologic Sponsor: Replimune, Inc.
๐ฉบ Plain-English Summary (8th-Grade Level)
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: University of Birmingham Alabama โ Birmingham, Alabama
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (51 Sites)
- University of Birmingham Alabama โ Birmingham, Alabama
- Banner MD Anderson Cancer Center โ Gilbert, Arizona
- Mayo Clinic โ Phoenix, Arizona
- Carti Cancer Center โ Little Rock, Arkansas
- UC San Diego โ La Jolla, California
- University of Southern California โ Los Angeles, California
- UCLA โ Los Angeles, California
- University of California, Irvine โ Orange, California
- University of California- San Francisco โ San Francisco, California
- Sylvester Comprehensive Cancer Center- University of Miami โ Miami, Florida
- University of Iowa-Cancer Center Research โ Iowa City, Iowa
- James Graham Brown Cancer Center- University of Louisville โ Louisville, Kentucky
- Mayo Clinic โ Rochester, Minnesota
- New York University Clinical Cancer Center โ New York, New York
- Weill Cornell Medical College โ New York, New York
- University of Rochester Medical Center โ Rochester, New York
- Duke Cancer Center โ Durham, North Carolina
- University of Cincinnati Medical Center โ Cincinnati, Ohio
- Providence Portland Medical Center โ Portland, Oregon
- MUSC Health โ Charleston, South Carolina
- West Cancer Center โ Germantown, Tennessee
- The University of Texas MD Anderson Cancer Center โ Houston, Texas
- Eccles Outpatient Care Center- Oncology Clinical Trials โ Murray, Utah
- Intermountain Cancer Center- Saint George Cancer Center โ St. George, Utah
- Seattle Cancer Care Alliance- University of Washington โ Seattle, Washington
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.